Spacing Out Cancer Immunotherapy: Can It Work as Well?

This trial is testing whether immunotherapy (checkpoint inhibitors like anti-PD-1 or anti-PD-L1 antibodies) can work just as well when given less often—every 3 months instead of every 2 weeks—for patients whose cancers have responded well to treatment. You would only be eligible if your cancer has already improved after 6 months of standard immunotherapy, and the trial will randomly assign you to either keep getting the medication on the regular schedule or switch to a less frequent schedule.

Doctors and patients are unsure how long to keep giving immunotherapy, especially when it's working. Some evidence suggests the medication stays active in your body much longer than the current dosing schedule requires, and giving it less frequently might reduce side effects, hospital visits, and costs without losing effectiveness. This trial will provide the first solid evidence to answer this important question.